These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28604554)

  • 1. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
    Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
    J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute visual loss after ipilimumab treatment for metastatic melanoma.
    Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
    J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
    Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
    Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
    Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
    Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
    Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
    Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
    [No Abstract]   [Full Text] [Related]  

  • 7. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
    Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
    Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
    Jørgensen LB; Yderstræde K
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Orbital myositis associated with ipilimumab].
    Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
    Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.
    Garcia-Neuer M; Marmarelis ME; Jangi SR; Luke JJ; Ibrahim N; Davis M; Weinberg J; Donahue H; Bailey N; Hodi FS; Buchbinder EL; Ott PA
    Cancer Immunol Res; 2017 Apr; 5(4):286-291. PubMed ID: 28373217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab-induced hypophysitis, a single academic center experience.
    Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
    Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 15. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
    Abdallah AO; Herlopian A; Ravilla R; Bansal M; Chandra-Reddy S; Mahmoud F; Ong S; Gokden M; Hutchins L
    J Oncol Pharm Pract; 2016 Jun; 22(3):537-42. PubMed ID: 25712627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
    Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
    Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
    Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
    Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
    Dika E; Ravaioli GM; Fanti PA; Piraccini BM; Lambertini M; Chessa MA; Baraldi C; Ribero S; Andrea A; Melotti B; Patrizi A
    Eur J Dermatol; 2017 Jun; 27(3):266-270. PubMed ID: 28524050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.